Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase.
about
Isolation and expression of novel human glutamate carboxypeptidases with N-acetylated alpha-linked acidic dipeptidase and dipeptidyl peptidase IV activityPurification, cDNA cloning, and expression of a new human blood plasma glutamate carboxypeptidase homologous to N-acetyl-aspartyl-alpha-glutamate carboxypeptidase/prostate-specific membrane antigenMolecular cloning of transferrin receptor 2. A new member of the transferrin receptor-like familySTEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumorsCloning and characterization of a novel peptidase from rat and human ileumStructure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancerPositron emission tomography imaging of prostate cancerAptamers in TherapeuticsChemoaffinity capture of pre-targeted prostate cancer cells with magnetic beadsMolecular identification of β-citrylglutamate hydrolase as glutamate carboxypeptidase 3Isolation and expression of a rat brain cDNA encoding glutamate carboxypeptidase IIThe cloning and characterization of a second brain enzyme with NAAG peptidase activityNAAG peptidase inhibition in the periaqueductal gray and rostral ventromedial medulla reduces flinching in the formalin model of inflammationAdvances in understanding the peptide neurotransmitter NAAG and appearance of a new member of the NAAG neuropeptide familyGroup II mGluR agonist LY354740 and NAAG peptidase inhibitor effects on prepulse inhibition in PCP and D-amphetamine models of schizophrenia.Phenotypic characterization of mice heterozygous for a null mutation of glutamate carboxypeptidase II.Phencyclidine and dizocilpine induced behaviors reduced by N-acetylaspartylglutamate peptidase inhibition via metabotropic glutamate receptors.PSMA mimotope isolated from phage displayed peptide library can induce PSMA specific immune response.Construction of prostate-specific expressed recombinant plasmids with high transcriptional activity of prostate-specific membrane antigen (PSMA) promoter/enhancer.Folylpoly-gamma-glutamate carboxypeptidase from pig jejunum. Molecular characterization and relation to glutamate carboxypeptidase II.The molecular pruning of a phosphoramidate peptidomimetic inhibitor of prostate-specific membrane antigen.A novel cytoplasmic tail MXXXL motif mediates the internalization of prostate-specific membrane antigen.N-substituted glutamyl sulfonamides as inhibitors of glutamate carboxypeptidase II (GCP2).Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidaseEngineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy.Prostate specific membrane antigen (PSMA) regulates angiogenesis independently of VEGF during ocular neovascularization.Extracellular proteases as targets for drug developmentA targeted low molecular weight near-infrared fluorescent probe for prostate cancer.Targeted inhibition of prostate cancer metastases with an RNA aptamer to prostate-specific membrane antigen.Spacer length effects on in vitro imaging and surface accessibility of fluorescent inhibitors of prostate specific membrane antigenInduction of autoantibodies to syngeneic prostate-specific membrane antigen by xenogeneic vaccination.Substrate specificity of prostate-specific membrane antigen.Targeting prostate cancer cells with a multivalent PSMA inhibitor-guided streptavidin conjugate.Phosphoramidate derivatives of hydroxysteroids as inhibitors of prostate-specific membrane antigen.Targeting prostate cancer cells with PSMA inhibitor-guided gold nanoparticles.The homodimer of prostate-specific membrane antigen is a functional target for cancer therapyNew gene expressed in prostate: a potential target for T cell-mediated prostate cancer immunotherapyExpression of PSMA in tumor neovasculature of high grade sarcomas including synovial sarcoma, rhabdomyosarcoma, undifferentiated sarcoma and MPNST.Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancerPET imaging in prostate cancer: focus on prostate-specific membrane antigen
P2860
Q22009067-0B027ACF-208F-425D-80A0-ABFB0194AC3FQ22009409-2A94F12A-CB36-4F84-987A-9FB568BF867AQ22010394-A90E19E2-1A02-44CB-9622-AB122CB7D6F5Q22010908-2D180EFE-D06F-464B-A670-95E35550B5E6Q24310730-F6FAA0EC-30D4-4F40-9EDF-573CE63F415CQ24542039-346581F1-4BA7-4903-BA74-75D8B9353F23Q24596241-2438D659-5C68-465D-8DDC-4CBB305D3627Q26738413-CF2E66E6-1B03-455B-9CA5-CFA88E4927A4Q26861322-A8CC3B65-D9D5-4470-91F7-83230D4F0252Q28508757-8805B01E-062D-483C-B6C1-FB1D0572DED0Q28572589-979157D4-24AC-4085-A424-152E2D532842Q28589768-7AF05D9D-B954-40FF-942C-2D3961C60C25Q30459203-5E4A6F84-2C66-49BF-8E90-2F4651F89E2CQ30465259-5AC72C43-894F-4CB4-9E62-A3E7ECBFB420Q30466262-8F9F8FF5-2B6A-4F65-B448-75B193389D72Q30480306-4E0495D2-FD6C-4AA9-8C18-18732DB8F023Q30491856-A7537BB4-CFF4-4B1F-93A6-4030873AA51AQ30831917-80EC0F9A-3E56-4093-AB50-3FAE64C55E4FQ31147626-33A23370-F805-4581-8158-56D03DD634C2Q32048229-2AFC3903-65F8-4330-BB8F-59465F5D98C6Q33299095-B0BC5271-8A33-48AB-9642-EF2304D3FBD9Q33763004-DC5E4B89-9B74-4D6C-B974-0DB511C40B4BQ33789515-2F825C63-8FBA-4454-B16D-3400F743E784Q33936498-1EAD86BE-57AB-40C8-A58B-0CA167DD11B8Q34284930-BCA9FF42-B716-45D2-BFE7-10BE3942E5E2Q34345914-0C8822F6-A60D-417F-8473-9AD2734DEC84Q35116202-A674B3D2-AA3D-4FAB-9C49-195718C714CDQ35446801-5C54CFE7-92EE-4B78-8D95-8B37CE3DC78DQ35600421-DDFB3AF7-D8CD-4ED9-860D-477E86AE82CAQ35926706-912E87B1-5F84-46BA-B0CD-E72ED1B3A67DQ35948223-EFCE2778-6662-4F77-9FF5-2AC146A2C00EQ36054736-E10678F3-B057-48B8-B1C7-77918862D879Q36477594-49EB3A7F-BFF8-4836-8604-8394FFB721BEQ36478758-5BC9D0F8-6345-4033-92DE-380864B6B28EQ36501550-171FBF9D-5C01-4AD2-BE02-D23F67A3F013Q36689474-2E01E471-9069-4ACC-A4B4-58F1A8F53299Q37435333-5CEBFAB1-B9D5-4177-962A-2C802CFF4E27Q37706172-4FBB9AC9-0F77-4D74-A609-3C03B994D77BQ37972920-1F1599F8-2A40-4A35-BBE3-120D83D64DFDQ38099369-B7EC8265-B645-42A6-BD16-8CC82D428BE1
P2860
Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase.
description
1996 nî lūn-bûn
@nan
1996 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
Prostate-specific membrane ant ...... teristics of a neuropeptidase.
@ast
Prostate-specific membrane ant ...... teristics of a neuropeptidase.
@en
Prostate-specific membrane ant ...... teristics of a neuropeptidase.
@nl
type
label
Prostate-specific membrane ant ...... teristics of a neuropeptidase.
@ast
Prostate-specific membrane ant ...... teristics of a neuropeptidase.
@en
Prostate-specific membrane ant ...... teristics of a neuropeptidase.
@nl
prefLabel
Prostate-specific membrane ant ...... teristics of a neuropeptidase.
@ast
Prostate-specific membrane ant ...... teristics of a neuropeptidase.
@en
Prostate-specific membrane ant ...... teristics of a neuropeptidase.
@nl
P2093
P2860
P356
P1476
Prostate-specific membrane ant ...... teristics of a neuropeptidase.
@en
P2093
A R Feldman
R E Carter
P2860
P304
P356
10.1073/PNAS.93.2.749
P407
P577
1996-01-01T00:00:00Z